Vitreoretinal disease in the coming decade

Current Opinion in Ophthalmology

Volumn 21, Issue 3, 2010, Pages 197-202

  Chiang, Allen ^a   Haller, Julia A ^a  

^a WILLS EYE HOSPITAL   (United States)

Author keywords

Artificial vision; Nanomedicine; Ocular gene therapy; Pharmacologic vitreolysis; Retinal stem cell therapy; Sustained release intravitreal dexamethasone

Indexed keywords

CHONDROITIN ABC LYASE; COMPLEMENTARY DNA; DEXAMETHASONE; DISPASE; FLUOCINOLONE; HYALURONIDASE; ISOMEROHYDROLASE; LIPOSOME; MICROPLASMIN; NANOPARTICLE; OZURDEX; PLASMIN; POLYGLACTIN; PROTEIN LCA 2; RECOMBINANT DNA; RECOMBINANT ENZYME; TRIAMCINOLONE; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG POTENCY; DRUG TOLERABILITY; EPIRETINAL MEMBRANE; GENE THERAPY; GENE VECTOR; HUMAN; INTRAOCULAR PRESSURE; NANOTECHNOLOGY; OXIDATIVE STRESS; PHOTORECEPTOR; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA HOLE; RETINITIS PIGMENTOSA; RETINOSCHISIS; REVIEW; SLOW DRUG RELEASE; STEM CELL TRANSPLANTATION; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRAL GENE THERAPY; VIRUS RECOMBINANT; VISUAL ACUITY; VITREOMACULAR TRACTION; VITREOMACULAR TRACTION SYNDROME; VITREORETINOPATHY;

DRUG DELIVERY SYSTEMS; EYE DISEASES; GENE THERAPY; HUMANS; RETINAL DISEASES; STEM CELL TRANSPLANTATION; VITREOUS BODY;

EID: 77951295070     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32833866db     Document Type: Review

References (45)

1. Machemer R, Parel JM, Norton EW. Vitrectomy: a pars plana approach. Technical improvements and further results. Trans Am Acad Ophthalmol Otolaryngol 1972; 76:462-466.
2. Gandorfer A, Ulbig M, Kampik A. Plasmin-assisted vitrectomy eliminates cortical vitreous remnants. Eye (Lond) 2002; 16:95-97.
3. Trese MT. Enzymatic vitreous surgery. Semin Ophthalmol 2000; 15:116-121.
4. Hermel M, Schrage NF. Efficacy of plasmin enzymes and chondroitinase ABC in creating posterior vitreous separation in the pig: a masked, placebocontrolled in vivo study. Graefes Arch Clin Exp Ophthalmol 2007; 245:399-406.
5. Hikichi T, Kado M, Yoshida A. Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit. Retina 2000; 20:195-198.
6. Narayanan R, Kuppermann BD. Hyaluronidase for pharmacologic vitreolysis. Dev Ophthalmol 2009; 44:20-25.
7. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005; 140:585-597.
8. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005; 140:573-584.
9. Oliveira LB, Tatebayashi M, Mahmoud TH, et al. Dispase facilitates posterior vitreous detachment during vitrectomy in young pigs. Retina 2001; 21:324-331.
10. Tezel TH, Del Priore LV, Kaplan HJ. Posterior vitreous detachment with dispase. Retina 1998; 18:7-15.
11. Trese MT, Williams GA, Hartzer MK. A new approach to stage 3 macular holes. Ophthalmology 2000; 107:1607-1611.
12. Margherio AR, Margherio RR, Hartzer M, et al. Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes. Ophthalmology 1998; 105:1617-1620.
13. Gandorfer A, Rohleder M, Sethi C, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 2004; 45:641-647.
14. Williams JG, Trese MT, Williams GA, HartzerMK. Autologous plasmin enzyme in the surgical management of diabetic retinopathy. Ophthalmology 2001; 108:1902-1905; discussion 5-6.
15. Uemura A, Nakamura M, Kachi S, et al. Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy. Arch Ophthalmol 2005; 123:209-213.
16. Kohno T, Sorgente N, Ishibashi T, et al. Immunofluorescent studies of fibronectin and laminin in the human eye. Invest Ophthalmol Vis Sci 1987; 28:506-514. (Pubitemid 17040860)
17. Asami T, Terasaki H, Kachi S, et al. Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema. Ophthalmology 2004; 111:231-237.
18. Quiram PA, Leverenz VR, Baker RM, et al. Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels. Retina 2007; 27:1090-1096.
19. Stefansson E, Loftsson T. The Stokes-Einstein equation and the physiological effects of vitreous surgery. Acta Ophthalmol Scand 2006; 84:718-719.
20. de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology 2009; 116:1349-1355; 55 e1-2.
21. Stalmans P, editor. MIVI-2T Trial: a randomized, double-masked, clinical trial of microplasmin intravitreal injection for nonsurgical treatment of vitreomacular traction. In: Proceedings of the ASRS 25th Annual Meeting; December 2007; Palm Springs, California.
22. Williams GA, editor. Phase IIb MIVI III: Microplasmin for Vitreous Injection Trial. In: Proceedings of the World Ophthalmology Congress; 28 June 2008; Hong Kong.
23. Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009; 29:46-51.
24. Allergan, Inc., data on file. [database on the Internet]; 2006-2007.
25. Haller JA. 6-month randomized controlled clinical trial of an intravitreal dexamethasone implant in macular edema associated with retinal vein occlusion. In: Proceedings of the Retina Congress 2009; 4 October 2009; New York, NY.
26. Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posteriorsegment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009; 147:1048-1054; 54 e1-2.
27. Yoncheva K, Gomez S, Campanero MA, et al. Bioadhesive properties of pegylated nanoparticles. Expert Opin Drug Deliv 2005; 2:205-218.
28. Hironaka K, Inokuchi Y, Tozuka Y, et al. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J Control Release 2009; 136:247-253.
29. Kim JH, Kim KW, KimMH, et al. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology 2009; 20:505101.
30. Beatty S, Koh H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45:115-134.
31. Yu DY, Cringle SJ. Retinal degeneration and local oxygen metabolism. Exp Eye Res 2005; 80:745-751.
32. Chen J, Patil S, Seal S, et al. Nanoceria particles prevent ROI-induced blindness. Adv Exp Med Biol 2008; 613:53-59.
33. Bennicelli J, Wright JF, Komaromy A, et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther 2008; 16:458-465.
34. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-2248.
35. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009; 374:1597-1605.
36. Johnson TV, Bull ND, Martin KR. Transplantation prospects for the inner retina. Eye (Lond) 2009; 23:1980-1984.
37. Baker PS, Brown GC. Stem-cell therapy in retinal disease. Curr Opin Ophthalmol 2009; 20:175-181.
38. Coles BL, Angenieux B, Inoue T, et al. Facile isolation and the characterization of human retinal stem cells. Proc Natl Acad Sci U S A 2004; 101:15772-15777.
39. Banin E, Obolensky A, Idelson M, et al. Retinal incorporation and differentiation of neural precursors derived from human embryonic stem cells. Stem Cells 2006; 24:246-257.
40. Sakaguchi DS, Van Hoffelen SJ, Theusch E, et al. Transplantation of neural progenitor cells into the developing retina of the Brazilian opossum: an in vivo system for studying stem/progenitor cell plasticity. Dev Neurosci 2004; 26 (5-6):336-345.
41. Jones BW, Marc RE. Retinal remodeling during retinal degeneration. Exp Eye Res 2005; 81:123-137.
42. Lu B, Malcuit C, Wang S, et al. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells 2009; 27:2126-2135.
43. Horsager A, Greenberg RJ, Fine I. Spatiotemporal interactions in retinal prosthesis subjects. Invest Ophthalmol Vis Sci 2010; 51:1223-1233.
44. Stieglitz T. Development of a micromachined epiretinal vision prosthesis. J Neural Eng 2009; 6:65005.
45. Chader GJ, Weiland J, Humayun MS. Artificial vision: needs, functioning, and testing of a retinal electronic prosthesis. Prog Brain Res 2009; 175:317-332.